Details

Autor(en) / Beteiligte

• Davis, Bionca M.
• Blake, Ian
• Panicker, Gitika
• Meites, Elissa
• Thompson, Gail
• Geis, Jesse
• Bruden, Dana
• Fischer, Marc
• Singleton, Rosalyn
• Unger, Elizabeth R.
• Markowitz, Lauri E.
• Bruce, Michael G.

Titel

Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9–14 years at 5 years after vaccination

Ist Teil von

• Vaccine, 2024-05, Vol.42 (14), p.3277-3281

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2024

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Persistent human papillomavirus (HPV) infection can cause anogenital and oropharyngeal cancers. Many HPV infections and HPV-associated cancers are vaccine-preventable. Studies suggest long-term persistence of vaccine-induced antibodies. However, data are limited among Alaska Native people. During 2011–2014, we enrolled Alaska Native children aged 9–14 years who received a 3-dose series of quadrivalent HPV vaccine (4vHPV). We collected sera at 1 month and 1, 2, 3, and 5 years post-vaccination to evaluate trends in type-specific immunoglobulin G antibody concentrations for the 4vHPV types (HPV 6/11/16/18). All participants (N = 469) had detectable antibodies against all 4vHPV types at all timepoints post-vaccination. For all 4vHPV types, antibody levels peaked by 1 month post-vaccination and gradually declined in subsequent years. At 5 years post-vaccination, antibody levels were higher among children who received 4vHPV at a younger age. Alaska Native children maintained antibodies against all 4vHPV types at 5 years post-vaccination.